Published in Gut on February 01, 2001
A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol (2014) 1.60
A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. Behav Res Ther (2011) 1.18
Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.14
Irritable bowel syndrome: a clinical review. World J Gastroenterol (2014) 1.10
Evaluation of the Birmingham IBS symptom questionnaire. BMC Gastroenterol (2008) 1.06
Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care. BMC Gastroenterol (2012) 0.96
Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol (2003) 0.95
Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). BMC Gastroenterol (2010) 0.94
A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract (2004) 0.94
Acupuncture for irritable bowel syndrome: a protocol for a pragmatic randomised controlled trial. BMC Gastroenterol (2010) 0.93
Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial. Dig Dis Sci (2005) 0.91
Effectiveness of acupuncture to treat irritable bowel syndrome: a meta-analysis. World J Gastroenterol (2014) 0.87
Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther (2007) 0.83
Psychologic Therapies for Irritable Bowel Syndrome. Curr Treat Options Gastroenterol (2001) 0.82
Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J Gastroenterol (2012) 0.81
Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. BMC Gastroenterol (2013) 0.81
Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg (2012) 0.81
How to assess epidemiological studies. Postgrad Med J (2004) 0.80
The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J Neurogastroenterol Motil (2016) 0.79
Efficacy of turmeric in the treatment of digestive disorders: a systematic review and meta-analysis protocol. Syst Rev (2014) 0.75
Optimal management of constipation associated with irritable bowel syndrome. Ther Clin Risk Manag (2015) 0.75
History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. Prim Care Companion J Clin Psychiatry (2008) 0.75
Tegaserod and IBS: a perfect match? Gut (2003) 0.75
Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. Nutr Metab (Lond) (2016) 0.75
Effects of anti-secretory factor (ASF) on irritable bowel syndrome (IBS). A double-blind, randomized study. Scand J Prim Health Care (2008) 0.75
Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach. Gastroenterol Hepatol (N Y) (2006) 0.75
Medical treatment of irritable bowel syndrome. Clin Colon Rectal Surg (2005) 0.75
Effect of diet and individual dietary guidance on gastrointestinal endocrine cells in patients with irritable bowel syndrome (Review). Int J Mol Med (2017) 0.75
Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. Clin Gastroenterol Hepatol (2017) 0.75
Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Therap Adv Gastroenterol (2017) 0.75
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Towards positive diagnosis of the irritable bowel. Br Med J (1978) 12.79
Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials (1995) 9.85
Irritable bowel, irritable body, or irritable brain? BMJ (1995) 2.11
Ranking of symptoms by patients with the irritable bowel syndrome. BMJ (1989) 1.87
Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. Gastroenterology (1990) 1.62
Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc (1992) 1.53
Review article: irritable bowel syndrome. Aliment Pharmacol Ther (1997) 1.51
Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis'. Indian J Gastroenterol (1997) 1.35
Double blind study of ispaghula in irritable bowel syndrome. Gut (1987) 1.35
Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci (1987) 1.23
Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol (1998) 1.17
Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. Gut (1987) 1.15
Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci (1994) 1.13
Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study. Dig Dis Sci (1994) 1.12
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (1994) 1.12
Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci (1995) 1.10
Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. Acta Gastroenterol Latinoam (1995) 1.09
Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther (1996) 1.06
Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study. Dig Dis Sci (1994) 1.05
Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol (1997) 1.04
A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol (1996) 1.04
Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl (1987) 1.01
Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl (1987) 0.99
Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (1994) 0.99
A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol (1996) 0.99
Stress management for irritable bowel syndrome: a controlled trial. Digestion (1991) 0.96
Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol (1996) 0.96
Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care (1989) 0.94
"Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol (1991) 0.87
Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion (1997) 0.87
Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy (1991) 0.86
[The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon]. Fortschr Med (1990) 0.84
Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol (1988) 0.84
Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome. A pilot multicenter clinical study. Ann N Y Acad Sci (1994) 0.84
The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol (1998) 0.84
Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome. Aliment Pharmacol Ther (1989) 0.83
Therapy of irritable bowel syndrome--an overview. Digestion (1995) 0.82
A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther (1995) 0.82
[Treatment of irritable bowel syndrome with peppermint oil. A double-blind study with a placebo]. Ugeskr Laeger (1988) 0.82
Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. Ital J Gastroenterol (1991) 0.82
Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther (1993) 0.81
Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther (1997) 0.81
The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome. Clin Neuropharmacol (1989) 0.80
[Otilonium bromide-diazepam in the treatment of the irritable colon. A controlled study versus otilonium bromide]. Clin Ter (1992) 0.79
Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study. Hepatogastroenterology (1992) 0.79
Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut (1990) 0.79
Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (1988) 0.79
[Treatment of irritable colon with lidamidine and support psychotherapy]. Rev Gastroenterol Mex (1997) 0.78
A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study. Br J Clin Pract (1990) 0.78
[The efficacy of Plantago ovata as a regulator of intestinal transit. A double-blind study compared to placebo]. Rev Esp Enferm Dig (1992) 0.77
Long-term treatment of irritable bowel syndrome: results of a randomized controlled trial. Q J Med (1989) 0.77
[Effect of a buzepide metiodide-haloperidol combination in treating functional intestinal disorders. Randomized double-blind controlled versus placebo study]. Ann Gastroenterol Hepatol (Paris) (1989) 0.77
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer (2006) 1.56
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess (2003) 0.99
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. Health Technol Assess (2010) 0.98
Amblyopia and quality of life: a systematic review. Eye (Lond) (2011) 0.95
The clinical effectiveness and safety of prophylactic retinal interventions to reduce the risk of retinal detachment and subsequent vision loss in adults and children with Stickler syndrome: a systematic review. Health Technol Assess (2011) 0.92
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess (2009) 0.82